Leading medical device company to build Center for Excellence in Cellular Manufacturing in Greater Sacramento (Rancho Cordova)
March 28, 2022 13:42 ET
|
Greater Sacramento Economic Council
Sacramento (RANCHO CORDOVA), Calif., March 28, 2022 (GLOBE NEWSWIRE) -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), in partnership with the City of Rancho Cordova and the Greater Sacramento...
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update
March 14, 2022 07:30 ET
|
Gracell Biotechnologies Inc.
Plan to file U.S. IND for lead program FasTCAR-T GC012F for relapse and/or refractory multiple myeloma (RRMM) during second half of 2022Allogeneic TruUCAR-T GC502 currently being investigated in a...
Monthly information on share capital and company voting rights
March 10, 2022 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal...
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
January 26, 2022 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
Oncotelic Presenting at BiotechGate Digital Partnering
January 19, 2022 09:05 ET
|
Oncotelic Therapeutics, Inc.
OT-101 is Oncotelic’s RNA Therapeutic Against TGF-βOT-101 has completed over six clinical trials against solid tumors with good efficacyOT-101 is currently undergoing a phase 1b trial in combination...
Monthly information on share capital and company voting rights
January 11, 2022 16:30 ET
|
Cellectis Inc.
NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting...
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials
January 10, 2022 16:30 ET
|
Cellectis Inc.
• Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® Gene Editing or Allogene’s Manufacturing Process • Allogene to Initiate a Phase 2 Pivotal Clinical Trial of ALLO-501A in...
Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation
January 04, 2022 16:30 ET
|
Cellectis Inc.
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...
Monthly information on share capital and company voting rights
December 06, 2021 16:30 ET
|
Cellectis Inc.
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of...
Oncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA® for Mesothelioma
December 01, 2021 09:01 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...